157 related articles for article (PubMed ID: 24705411)
21. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic.
Rodriguez M; Monedero I; Caminero JA; Encarnación M; Dominguez Y; Acosta I; Muñoz E; Camilo E; Martinez-Selmo S; de los Santos S; del Granado M; Casals M; Cayla J; Marcelino B
Int J Tuberc Lung Dis; 2013 Apr; 17(4):520-5. PubMed ID: 23485386
[TBL] [Abstract][Full Text] [Related]
22. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
[TBL] [Abstract][Full Text] [Related]
23. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health.
Telzak EE; Chirgwin KD; Nelson ET; Matts JP; Sepkowitz KA; Benson CA; Perlman DC; El-Sadr WM
Int J Tuberc Lung Dis; 1999 Apr; 3(4):337-43. PubMed ID: 10206505
[TBL] [Abstract][Full Text] [Related]
24. Nature of drug resistance and predictors of multidrug-resistant tuberculosis among patients seen at the Philippine General Hospital, Manila, Philippines.
Mendoza MT; Gonzaga AJ; Roa C; Velmonte MA; Jorge M; Montoya JC; Tan Torres T; Ong M; Barez MY; Ang CF
Int J Tuberc Lung Dis; 1997 Feb; 1(1):59-63. PubMed ID: 9441060
[TBL] [Abstract][Full Text] [Related]
25. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.
Kurbatova EV; Gammino VM; Bayona J; Becerra MC; Danilovitz M; Falzon D; Gelmanova I; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riekstina V; Taylor A; Viiklepp P; Zignol M; Cegielski JP
Int J Tuberc Lung Dis; 2012 Oct; 16(10):1335-43. PubMed ID: 23107633
[TBL] [Abstract][Full Text] [Related]
26. High correlation of clinical criteria in the diagnosis of drug-resistant TB and prevalence of ofloxacin resistance.
Kumar R; Garg R; Kant S; Verma SK; Kushwaha RA; Kumar S; Jain A
Int J Tuberc Lung Dis; 2016 Oct; 20(10):1354-1357. PubMed ID: 27725047
[TBL] [Abstract][Full Text] [Related]
27. Relatively low primary drug resistant tuberculosis in southwestern Ethiopia.
Abebe G; Abdissa K; Abdissa A; Apers L; Agonafir M; de-Jong BC; Colebunders R
BMC Res Notes; 2012 May; 5():225. PubMed ID: 22574696
[TBL] [Abstract][Full Text] [Related]
28. Drug resistance profile of Mycobacterium tuberculosis and predictors associated with the development of drug resistance.
Hameed S; Ahmad SR; Rahman MAU; Nazir H; Ullah I
J Glob Antimicrob Resist; 2019 Sep; 18():155-159. PubMed ID: 30910744
[TBL] [Abstract][Full Text] [Related]
29. A cross-sectional study of tuberculosis drug resistance among previously treated patients in a tertiary hospital in Accra, Ghana: public health implications of standardized regimens.
Forson A; Kwara A; Kudzawu S; Omari M; Otu J; Gehre F; de Jong B; Antonio M
BMC Infect Dis; 2018 Apr; 18(1):149. PubMed ID: 29606091
[TBL] [Abstract][Full Text] [Related]
30. [Frequency of drug resistant tuberculosis in Poland in 2000 as compared to 1997].
Augustynowicz-Kopeć E; Zwolska Z; Jaworski A; Kostrzewa E; Klatt M; Swiderska A; Drozd I
Pneumonol Alergol Pol; 2002; 70(3-4):193-202. PubMed ID: 12271966
[TBL] [Abstract][Full Text] [Related]
31. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
32. Pulmonary resection in the treatment of 43 patients with well-localized, cavitary pulmonary multidrug-resistant tuberculosis in Shanghai.
Xie B; Yang Y; He W; Xie D; Jiang G
Interact Cardiovasc Thorac Surg; 2013 Sep; 17(3):455-9. PubMed ID: 23748869
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of acquired MDR-TB and HIV co-infection.
Deivanayagam CN; Rajasekaran S; Venkatesan R; Mahilmaran A; Ahmed PR; Annadurai S; Kumar S; Chandrasekar C; Ravichandran N; Pencillaiah R
Indian J Chest Dis Allied Sci; 2002; 44(4):237-42. PubMed ID: 12437236
[TBL] [Abstract][Full Text] [Related]
34. Frequency of Circulating CD4
Ferrian S; Ross M; Conradie F; Vally Omar S; Ismail N; Little F; Kaplan G; Fallows D; Gray CM
Front Immunol; 2018; 9():2438. PubMed ID: 30410488
[TBL] [Abstract][Full Text] [Related]
35. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
[TBL] [Abstract][Full Text] [Related]
36. Implementation of the INNO-LiPA Rif. TB® line-probe assay in rapid detection of multidrug-resistant tuberculosis in Latvia.
Skenders GK; Holtz TH; Riekstina V; Leimane V
Int J Tuberc Lung Dis; 2011 Nov; 15(11):1546-52, i. PubMed ID: 22008771
[TBL] [Abstract][Full Text] [Related]
37. Pattern of first- and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan.
Javaid A; Hasan R; Zafar A; Chaudry MA; Qayyum S; Qadeer E; Shaheen Z; Agha N; Rizvi N; Afridi MZ; Chima MK; Khan AR; Ghafoor A; Khan S; Awan SR; Akhtar S; Choudry K; Iqbal ZH; Ansarie M; Ahmad N
Int J Tuberc Lung Dis; 2017 Mar; 21(3):303-308. PubMed ID: 28225340
[TBL] [Abstract][Full Text] [Related]
38. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
[TBL] [Abstract][Full Text] [Related]
39. Highly successful treatment outcome of multidrug-resistant and genetic diversity of multidrug-resistant Mycobacterium tuberculosis strains in Rwanda.
Muvunyi CM; Ngabonziza JCS; Uwimana I; Harelimana JD; Mucyo Y; Sebatunzi OR; Muvunyi TZ; Seruyange E; Masaisa F; Mazarati JB; Gasana M
Trop Med Int Health; 2019 Jul; 24(7):879-887. PubMed ID: 31066112
[TBL] [Abstract][Full Text] [Related]
40. Sensitivity Pattern of Second Line Anti-Tuberculosis Drugs against Clinical Isolates of Multidrug Resistant Mycobacterium tuberculosis.
Ghafoor T; Ikram A; Abbasi SA; Zaman G; Ayyub M; Palomino JC; Vandamme P; Martin A
J Coll Physicians Surg Pak; 2015 Apr; 25(4):250-3. PubMed ID: 25899188
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
